Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Colorectal Cancer in a Younger Population

April 2nd 2021

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Dr. Wainberg on the Potential Role of Neoadjuvant Chemotherapy in Pancreatic Cancer

April 1st 2021

Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.

FDA Grants Breakthrough Therapy Designation to Futibatinib for FGFR2+ Advanced Cholangiocarcinoma

April 1st 2021

The FDA has granted a breakthrough therapy designation to the FGFR inhibitor futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 gene rearrangements, including fusions.

HCC Treatment: Emerging Data in IO Combinations

April 1st 2021

Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.

Ongoing Data for First-line Combinations in HCC

April 1st 2021

A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.

Approaching Second-Line Therapy in HCC

March 31st 2021

Amit Singal, MD, shares his thoughts on approaching second-line therapy for HCC (hepatocellular carcinoma) after first-line atezolizumab-bevacizumab as well as options for patients with Child-Pugh B disease who are ineligible for frontline atezolizumab-bevacizumab.

KEYNOTE-240 and HIMALAYA Trials in Advanced HCC

March 31st 2021

A review of currently available ongoing data for unresectable HCC (hepatocellular carcinoma), including data from the HIMALAYA trial.

Study Tests Guidelines for Monitoring Pancreatic Cysts

March 30th 2021

Investigators are seeking to determine the optimal protocol for monitoring patients with pancreatic cysts to better identify neoplasms that are more likely to become malignant.

Treating Unresectable, Advanced Cholangiocarcinoma

March 29th 2021

Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.

Neoadjuvant Therapy for Advanced Cholangiocarcinoma

March 29th 2021

An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.

Single Priming Dose of Tremelimumab Plus Durvalumab Shows Encouraging Clinical Activity, Safety in Advanced HCC

March 28th 2021

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.

Burst of Treatment Options in HCC Complicates Sequencing Decisions

March 27th 2021

Options for systemic treatment for patients with hepatocellular carcinoma have significantly expanded since 2017, when the sole available option was sorafenib. Now, the arsenal includes checkpoint inhibitors, targeted therapies, and combinations of both classes of drugs.

Immunotherapy Begins to Make Its Way Into Early- and Intermediate-Stage HCC

March 26th 2021

Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.

Novel Combinations Flood the Frontline Treatment Landscape in Advanced HCC

March 26th 2021

Combinations of checkpoint inhibitors and VEGF TKIs, as well as dual checkpoint blockade, are affording patients with advanced hepatocellular carcinoma greater potential for disease control and deep, long-lasting responses, underscoring the need for biomarkers of response to combination regimens and single-agent TKIs, the latter of which still play a role for select populations.

Dr. Singal on Downstaging Strategies in HCC

March 26th 2021

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

Role of TKIs in HCC Treatment

March 25th 2021

An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.

Treatment Strategies for Childs-Pugh B Disease

March 25th 2021

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

Frontline Trials for Unresectable HCC

March 25th 2021

Amit Singal, MD, MS, and Stephen L. Chan, MD, review the IMbrave150, LEAP-002, and CheckMate 9DW trials for unresectable hepatocellular carcinoma.

TACE-3 and CheckMate 74W Trials for BCLC stage B or stage C HCC

March 25th 2021

Stephen L. Chan, MD, reviews data from key trials of emerging combinations of TACE (transarterial chemoembolization), plus systemic therapies for BCLC (Barcelona Clinic Liver Cancer) stage B or C hepatocellular carcinoma.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.